Angelini Ventures Enters Asia — and Signals a Bigger Healthcare Play

A €300M evergreen fund, AI-backed deal platform, and public–private partnerships reveal a long-term Europe–Asia healthcare strategy.

Angelini Ventures, the healthcare investment arm of Italy’s Angelini Industries, has officially opened its first Asian regional office in Singapore. Located in the Central Business District, the new hub places the firm in the centre of Asia’s rapidly growing biotech and healthtech ecosystem — and signals a clear goal to scale transformative healthcare solutions across the region.

The move includes a partnership with Enterprise Singapore to mentor and support local biomedical and healthtech startups aiming to expand into Europe and global markets. For Angelini Ventures, Singapore is not just a base — it is a bridge between Asia’s innovation capabilities and international commercialisation pathways.

A Strategic €300 Million Healthcare Fund

Angelini Ventures manages €300 million in evergreen capital and focuses on early-stage companies in biotech, life sciences and digital health. Since October 2022, it has invested €125 million across 22 startups in Europe, North America and Asia — with a strong emphasis on technologies that can define the future of patient care.

Its first Asian investment came in May 2025, when it co-led a US$45 million Series B round for Nuevocor, a Singapore-based biotech company developing gene therapy treatments for genetic dilated cardiomyopathy. The deal marked Angelini Ventures’ entry into both Asia and the cardiovascular biotech space.

Why Singapore — and Why Now?

Angelini Industries CEO Sergio Marullo di Condojanni said Asia is now a key learning ground for healthcare trends that will shape the future of care globally.

“This new hun is a natural evolution of our commitment to making healthcare increasingly accessible and patient-centric on a global scale,” Sergio Marullo di Condojanni said.

CEO and Managing Director Paolo Di Giorgio highlighted Asia’s appeal as a hub for clinical translation, R&D and talent development. Strong government backing for biotech innovation and increasing public–private collaboration make Singapore, he said, “the epicentre of growth for healthtech in the region.”

Leadership Grounded in Local and Global Experience

The new regional office will be led by Elia Stupka, who brings over 20 years of experience across industry, academia and genomics research. Earlier in his career, he collaborated with Nobel Laureate Dr Sydney Brenner to establish Singapore’s first genomics laboratory — a milestone that helped shape the country’s biomedical research foundation.

With this local scientific legacy and a global investment network, Angelini Ventures aims to identify high-potential ventures more effectively and connect them directly with international partners and markets.

Data-Driven Investing: The Intelligence Hub

To support scalable decision-making, the firm has developed the Angelini Ventures Intelligence Hub, an AI-powered platform that aggregates worldwide data on healthcare and life sciences startups. The system analyses raw information and turns it into actionable insights for deal sourcing and due diligence.

The platform will now be extended through the Singapore office to inform not just internal investment choices, but also ecosystem collaboration — helping founders, researchers and investors spot commercial opportunities faster and with better clarity.

Building a Europe–Asia Innovation Corridor

Beyond investment, Angelini Ventures is embedding itself into Singapore’s biomedical and deep tech landscape. A key initiative is Espresso Lab, a venture boost programme launched with Enterprise Singapore. It will offer selected startups access to tailored mentorship, regulatory guidance and international market navigation — particularly into Europe.

Additionally, a partnership with AI Singapore aims to build pathways for AI-driven healthcare solutions to reach commercial deployment. Joint programmes and pitch sessions will connect healthtech startups with industry experts, researchers and healthcare providers.

Conclusion: More Than an Office Opening

Angelini Ventures is not simply expanding geographically — it is positioning itself as a bridge between Asian science and European scale. By combining institutional capital, public-sector partnerships, AI-driven investment tools and deep domain expertise, its Singapore office is designed to enable long-term ecosystem building rather than short-term deal flow.

If this strategy succeeds, Singapore could evolve into a key junction where European investment, Asian innovation and global healthcare markets converge. For regional founders and investors, it signals the arrival of a new kind of healthcare capital — one that is strategic, data-driven and committed to building category-defining companies.

Quick Takeaways

• Angelini Ventures opened its first Asian office in Singapore to deepen healthtech and biotech investment.
  
• The VC manages a €300M evergreen fund and has already invested €125M in 22 startups globally.
  
• First Asian investment: Nuevocor — a Singapore biotech backed in a US$45M Series B round.
  
• A key focus is building a Europe–Asia innovation corridor, starting with the Espresso Lab programme.
  
• Its AI-powered Intelligence Hub will guide investment decisions and support ecosystem collaboration.
  
• Partnerships with EnterpriseSG and AI Singapore position the firm as a long-term player in the region’s healthcare innovation landscape.